Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biomarkers in chronic graft-versus-host disease: quo vadis?

Bone Marrow Transplantation volume 53, pages 832–837 (2018)Cite this article

Subjects

Abstract

Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urine-proteomics and cellular subsets (CD4+ T-cell subsets, NK cell subsets, and CD19+CD21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site—when a biomarker defines the indication. New Engl J Med. 2017;377:1409–12.

    Article  PubMed  Google Scholar 

  2. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2:e21–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21:266–74.

    Article  PubMed  Google Scholar 

  4. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11:945–56.

    Article  PubMed  Google Scholar 

  5. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12:126–37.

    Article  PubMed  Google Scholar 

  6. Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015;21:780–92.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1.

    Article  PubMed  Google Scholar 

  8. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34.

    Article  PubMed  Google Scholar 

  9. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123:786–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34:2583–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells. Blood. 2016;127:3082–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Dickinson AM, Norden J. Non-HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome? Int J Immunogenet. 2015;42:229–38.

    Article  PubMed  CAS  Google Scholar 

  13. Greinix HT, Kuzmina Z, Weigl R, Kormoczi U, Rottal A, Wolff D, et al. CD19 + CD21low B cells and CD4 + CD45RA + CD31 + T cells correlate with first diagnosis of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:250–8.

    Article  PubMed  CAS  Google Scholar 

  14. Weissinger EM, Human C, Metzger J, Hambach L, Wolf D, Greinix HT, et al. The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation. Leukemia. 2017;31:654–62.

    Article  PubMed  CAS  Google Scholar 

  15. Martin PJ, Fan W, Storer BE, Levine DM, Zhao LP, Warren EH, et al. Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood. 2016;128:2450–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13:6107–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Uhlin M, Mattsson J, Maeurer M. Update on viral infections in lung transplantation. Curr Opin Pulm Med. 2012;18:264–70.

    Article  PubMed  CAS  Google Scholar 

  18. Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, et al. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ann Hematol. 2015;94:1727–32.

    Article  PubMed  Google Scholar 

  19. Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant. 2016;22:1781–91.

    Article  PubMed  Google Scholar 

  20. Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746–56.

    Article  PubMed  CAS  Google Scholar 

  21. Kim D, Al-Dawsari G, Chang H, Panzarella T, Gupta V, Kuruvilla J, et al. Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT. Bone Marrow Transplant. 2013;48:1104–11.

    Article  PubMed  CAS  Google Scholar 

  22. Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant. 2015;21:1343–59.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA. 2017;318:557–66.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, et al. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017;129:162–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Bohmann EM, Fehn U, Holler B, Weber D, Holler E, Herr W, et al. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset. Ann Hematol. 2017;96:299–310.

    Article  PubMed  CAS  Google Scholar 

  26. Inamoto Y, Martin PJ, Paczesny S, Tabellini L, Momin AA, Mumaw CL, et al. Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23:1250–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Thorarinsdottir K, Camponeschi A, Gjertsson I, Martensson IL. CD21 -/low B cells: a snapshot of a unique B cell subset in health and disease. Scand J Immunol. 2015;82:254–61.

    Article  PubMed  CAS  Google Scholar 

  28. Kariminia A, Ivison S, Ng B, Rozmus J, Sung S, Varshney A, et al. CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica. 2017;102:1936–46.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant. 2015;21:589–603.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31–47.

    Article  PubMed  Google Scholar 

  31. Stift J, Baba HA, Huber E, Federmann B, Fischer HP, Schmitt-Graeff A, et al. Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation. Virchows Arch. 2014;464:175–90.

    Article  PubMed  Google Scholar 

  32. Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea. 2012;31:299–310.

    Article  PubMed  Google Scholar 

  33. Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N, et al. Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease. J Immunol. 2016;197:3490–503.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Ahmed SS, Wang XN, Norden J, Pearce K, El-Gezawy E, Atarod S, et al. Identification and validation of biomarkers associated with acute and chronic graft versus host disease. Bone Marrow Transplant. 2015;50:1563–71.

    Article  PubMed  CAS  Google Scholar 

  35. Kuzmina Z, Krenn K, Petkov V, Kormoczi U, Weigl R, Rottal A, et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121:1886–95.

    Article  PubMed  CAS  Google Scholar 

  36. Bruggen MC, Petzelbauer P, Greinix H, Contassot E, Jankovic D, French L, et al. Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease. J Invest Dermatol. 2015;135:999–1006.

    Article  PubMed  CAS  Google Scholar 

  37. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Bassim CW, Ambatipudi KS, Mays JW, Edwards DA, Swatkoski S, Fassil H, et al. Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J Clin Immunol. 2012;32:1390–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Cocho L, Fernandez I, Calonge M, Martinez V, Gonzalez-Garcia MJ, Caballero D, et al. Biomarkers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model. Invest Ophthalmol Vis Sci. 2016;57:746–58.

    Article  PubMed  CAS  Google Scholar 

  41. Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011;117:2275–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, et al. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res. 2016;22:319–27.

    Article  PubMed  CAS  Google Scholar 

  43. Whittle R, Taylor PC. Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. Blood. 2011;118:6446–9.

    Article  PubMed  CAS  Google Scholar 

  44. Kuzmina Z, Greinix HT, Knobler R, Worel N, Kouba M, Weigl R, et al. Proportions of immature CD19 + CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Blood. 2009;114:744–6.

    Article  PubMed  CAS  Google Scholar 

  45. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood. 2008;111:3276–85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Cuvelier GD, Kariminia A, Fujii H, Aslanian S, Wall D, Goldman F, et al. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children’s Oncology Groups Study, ASCT0031. Bone Marrow Transplant. 2010;45:1653–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:386–97.

    Article  PubMed  CAS  Google Scholar 

  48. Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children’s Oncology Group Study ASCT0031. Biol Blood Marrow Transplant. 2011;17:1804–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27 + B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:208–19.

    Article  PubMed  Google Scholar 

  50. Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127:646–57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Pidala J, Sigdel TK, Wang A, Hsieh S, Inamoto Y, Martin PJ, et al. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res. 2017;3:3–16.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

DW received support from the German José Carreras Foundation. The conference was supported by the Meredith A. Cowden foundation, Mallinckrodt, Incyte Inc., Gilead Sciences, Inc., Jazz Pharmaceuticals, Miltenyi, Metabolon, and Beckman Coulter.

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany

    D. Wolff, E. Holler & M. Edinger

  2. Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    H. Greinix

  3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    S. J. Lee, T. Gooley & J. A. Hansen

  4. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA

    S. Paczesny

  5. Experimental Transplantation and Immunology Branch, Center of Cancer Research, National Cancer Institute, Bethesda, MD, USA

    S. Pavletic & F. Hakim

  6. Hematology Department, Hôpital Saint-Antoine; Université Pierre & Marie Curie; and INSERM, Centre de Recherche Saint-Antoine, UMRS U938, Paris, France

    F. Malard

  7. Department of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA

    M. Jagasia

  8. St. Anna Children’s Hospital, Medical University Vienna, Vienna, Austria

    A. Lawitschka

  9. Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, and Medical School University of Zagreb, Zagreb, Croatia

    D. Pulanic

  10. Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia

    D. Pulanic

  11. Institute of Cellular Medicine, Newcastle University, Newcastle, UK

    A. Dickinson

  12. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

    E. Weissinger

  13. Department of Medicine, Division of Hematological Malignancies & Cellular Therapy, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA

    S. Sarantopoulos

  14. Michael Cuccione Childhood Cancer Research Program, British Columbia Children’s Hospital/University of British Columbia, Vancouver, BC, Canada

    K. R. Schultz

Authors
  1. D. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Greinix
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Gooley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Paczesny
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Pavletic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Hakim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Malard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Jagasia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Lawitschka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. A. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Pulanic
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. Holler
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Dickinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E. Weissinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M. Edinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S. Sarantopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. K. R. Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Wolff.

Ethics declarations

Conflict of interest

SP is an inventor on a patent on “Methods of detection of graft-versus-host disease” licensed to Viracor-IBT Laboratories. The remaining authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolff, D., Greinix, H., Lee, S.J. et al. Biomarkers in chronic graft-versus-host disease: quo vadis?. Bone Marrow Transplant 53, 832–837 (2018). https://doi.org/10.1038/s41409-018-0092-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0092-x

Search

Advanced search

Quick links